|Bid||190.02 x 900|
|Ask||190.05 x 1400|
|Day's Range||187.33 - 190.09|
|52 Week Range||134.53 - 197.86|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||52.78|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chairman & CEO of Edwards Lifesciences Corp (EW) Michael A Mussallem sold 22,850 shares of EW on 07/09/2019 at an average price of $189.14 a share.
EW has had some corrections and pullbacks along the way during this long and strong rally from $80 to nearly $200, but its price target is $240.
Edwards Lifesciences Corp NYSE:EWView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for EW with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.05 billion over the last one-month into ETFs that hold EW are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices. The agency said the company's voluntary recall of its IntraClude intra-aortic occlusion device in May has now been classified by the FDA as Class I. Class I recall is the strictest form of recall issued by the FDA, where use of faulty devices may cause serious injury or death.
Boston Scientific will likely top its own three-year guidance for a 6%-9% compound annual growth rate, analysts said Thursday as the medical technology company expands its heart devices.
While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Edwards Lifesciences Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...
Today we'll evaluate Edwards Lifesciences Corporation (NYSE:EW) to determine whether it could have potential as an...
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.
Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 05/10/2019 at an average price of $178.99 a share.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.